Visugromab

• Description :

  Visugromab (CTL-002) is a GDF-15 neutralizing IgG4 mAb. Visugromab has synergistic anticancer activity with the anti-PD1 antibody Nivolumab (HY-P9903) and can effectively act on PD-1/PD-L1 relapsed/refractory metastatic solid tumors. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) [1].

• Product Name Alternative :

  CTL-002

• UNSPSC :

  12352203

• Target :

  PD-1/PD-L1; TGF-beta/Smad

• Type :

  Inhibitory Antibodies

• Related Pathways :

  Immunology/Inflammation; Stem Cell/Wnt; TGF-beta/Smad

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/visugromab.html

• Purity :

  98.40

• Solubility :

  10 mM in DMSO|H2O

• Smiles :

  [Visugromab]

• Molecular Weight :

  (144.56 kDa)

• References & Citations :

  [1]Necchi A, et al. Neutralizing GDF-15 in muscle-invasive bladder cancer (MIBC) : A neoadjuvant immunotherapy trial of visugromab (CTL-002) in combination with the anti-PD1 antibody nivolumab (NEO-GDFATHER) [J]. 2023.|[2]Melero I, et al. Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours. Nature. 2025 Jan;637 (8048) :1218-1227.

• Shipping Conditions :

  Dry Ice

• Storage Conditions :

  Store at -80°C for 2 years

• Scientific Category :

  Inhibitory Antibodies

• Clinical Information :

  Phase 2

• CAS Number :

  [2556646-63-8]